- Conditions
- Persistent Atrial Fibrillation
- Interventions
- Computational Mapping Algorithm
- Device
- Lead sponsor
- Vivek Reddy
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 4
- States / cities
- Denver, Colorado • Boston, Massachusetts • New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1897–1920
of 21,535
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Atrial Fibrillation
- Interventions
- Same day discharge
- Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 19 Years to 74 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Chronic Sinusitis
- Interventions
- SPRC-AB01
- Drug
- Lead sponsor
- Naryx Pharma
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 43
- States / cities
- Hoover, Alabama • Jonesboro, Arkansas • Fresno, California + 40 more
- Conditions
- COVID-19, SARS-COV-2 Infection
- Interventions
- BNT162b2 Vaccine, Placebo
- Biological
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 50 Years to 64 Years
- Enrollment
- 5,240 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 196
- States / cities
- Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 148 more
- Conditions
- Phenylketonuria
- Interventions
- SYNB1934v1, Placebo
- Drug
- Lead sponsor
- Synlogic
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 14
- States / cities
- Culver City, California • Orange, California • Palo Alto, California + 11 more
- Conditions
- Adenocarcinoma, Non-small Cell Lung Cancer
- Interventions
- Erlotinib
- Drug
- Lead sponsor
- Pasi A. Janne, MD, PhD
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2019
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Crohn's Disease
- Interventions
- Infliximab, Placebo
- Biological · Drug
- Lead sponsor
- Janssen Biotech, Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 297 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 62
- States / cities
- Birmingham, Alabama • La Jolla, California • Orange, California + 59 more
- Conditions
- Autoimmune Hemolytic Anemia, Immune Thrombocytopenia
- Interventions
- KZR-616
- Drug
- Lead sponsor
- Kezar Life Sciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 15
- States / cities
- Los Angeles, California • San Francisco, California • Jacksonville, Florida + 12 more
- Conditions
- Advanced Solid Tumors
- Interventions
- LCB02A
- Drug
- Lead sponsor
- LigaChem Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 191 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Lake Success, New York • Charleston, South Carolina + 1 more
- Conditions
- Sclerosing Cholangitis
- Interventions
- Fecal Microbiota Transplantation
- Biological
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma
- Interventions
- AG-120, Placebo
- Drug
- Lead sponsor
- Institut de Recherches Internationales Servier
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 187 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 26
- States / cities
- Scottsdale, Arizona • Duarte, California • Irvine, California + 19 more
- Conditions
- Solid Tumor, Advanced Solid Tumor, Solid Tumor, Adult, Metastatic Tumor, Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Metastatic Ovarian Carcinoma, Endometrial Neoplasms, Endometrial Diseases, Metastatic Endometrial Cancer, Triple Negative Breast Cancer, Metastatic Endometrial Carcinoma, Advanced Endometrial Carcinoma, Advanced Ovarian Carcinoma, Gastric Cancer, Advanced Gastric Carcinoma, Metastatic Gastric Cancer, Metastatic Gastric Carcinoma, Small Cell Lung Cancer, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms, Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Carcinoma, CCNE1 Amplification, Hormone Receptor Negative Breast Carcinoma, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Progesterone-receptor-positive Breast Cancer
- Interventions
- NKT3964, Paclitaxel, Doxorubicin
- Drug
- Lead sponsor
- NiKang Therapeutics, Inc.
- Industry
- Eligibility
- 19 Years and older
- Enrollment
- 238 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 19
- States / cities
- Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 16 more
- Conditions
- Solid Tumor, Rhabdomyosarcoma
- Interventions
- Atezolizumab, Vincristine, Irinotecan, Temozolomide
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 6 Months to 30 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 7
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Cincinnati, Ohio + 4 more
- Conditions
- Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
- Interventions
- Sonesitatug vedotin, Rilvegostomig, Nivolumab, Capecitabine, 5-Fluorouracil, Oxaliplatin, Zolbetuximab, Leucovorin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 93
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 81 more
- Conditions
- Celiac Disease, Healthy
- Interventions
- OFDI Capsule
- Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 108 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2030
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Amputation, Traumatic, Amputation;Traumatic;Old, Face Injury, Face; Deformity, Abdominal Wall Defect
- Interventions
- IL-2
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Adenoid Cystic Carcinoma
- Interventions
- Radiation, Pembrolizumab
- Radiation · Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Fibromyalgia, Chronic Pain
- Interventions
- Tai Chi
- Behavioral
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Lamellar Ichthyosis
- Interventions
- CD5789 Cream 200 µg/g, CD5789 Cream 100 µg/g, CD5789 Cream Vehicle
- Drug
- Lead sponsor
- Mayne Pharma International Pty Ltd
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 10
- States / cities
- San Diego, California • Aurora, Colorado • New Haven, Connecticut + 7 more
- Conditions
- Gastroparesis, Gastroparesis-like Syndrome
- Interventions
- Not listed
- Lead sponsor
- Johns Hopkins Bloomberg School of Public Health
- Other
- Eligibility
- 8 Years to 25 Years
- Enrollment
- 216 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 6
- States / cities
- Boston, Massachusetts • Columbus, Ohio • El Paso, Texas + 2 more
- Conditions
- HIV, HIV Infections
- Interventions
- E/C/F/TAF, E/C/F/TDF, EFV/FTC/TDF, RTV, ATV, FTC/TDF, COBI
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,443 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 91
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 59 more
- Conditions
- Recurrent or Progressive Malignant Glioma
- Interventions
- ANG1005
- Drug
- Lead sponsor
- Angiochem Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 6
- States / cities
- Boston, Massachusetts • Detroit, Michigan • New York, New York + 3 more
- Conditions
- Heart Defects, Congenital
- Interventions
- Blalock-Taussig pulmonary artery shunt, Right ventricular to pulmonary artery shunt
- Procedure
- Lead sponsor
- Carelon Research
- Other
- Eligibility
- Not listed
- Enrollment
- 555 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Wilmington, Delaware • St. Petersburg, Florida + 9 more
- Conditions
- CLL/SLL
- Interventions
- Lisaftoclax
- Drug
- Lead sponsor
- Ascentage Pharma Group Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 7
- States / cities
- Duarte, California • Jacksonville, Florida • Boston, Massachusetts + 4 more